ESTRO 2023 - Abstract Book

S965

Digital Posters

ESTRO 2023

solitary lung metastasis. The median plasma EBV-DNA copies/ml. dropped from 544(at baseline) to 2(after NACT) (p<0.001) & subsequently became nil in all evaluable patients at 1 & 3 months post-CRT. The median duration of follow-up was 13.06 months. The median PFS & OS had not been reached. The actuarial PFS & OS rates were 100% & 90.3% at 1 year and 80.8% & 73.6% at 2 years, respectively. The incidence of severe haematological & non-haematological toxicities were 17.4% & 4.3% during NACT and 20% & 25% during CRT, respectively. No severe late toxicity was noted. Median MDADI-CS dipped from 94.73 to 56.84 post-CRT, with a steady rise to 89.71 and 93.15 at 3 & 6 months post-CRT, respectively (p-value<0.001), due to resolution of acute swallowing toxicities.

Conclusion GC-based NACT followed by cisplatin-enhanced Do-IMRT was feasible and led to high ORR & favourable toxicity profile in patients with LA-NPC.

PO-1207 Intensity-modulated radiotherapy for inoperable/unresectable recurrent differentiated thyroid cancer

J. Wu 1 , Y. Tsai 1

1 Koo Foundation Sun Yat-Sen Cancer Center, Radiation Oncology, Taipei, Taiwan

Purpose or Objective For differentiated thyroid cancers that recurred in the thyroid bed and/or regional nodal regions, first-line treatments include surgery, percutaneous ethanol injection, and radioactive iodine. However, for inoperable/unresectable lesions, there are few treatment options. Both tyrosine kinase inhibitors and external beam radiotherapy are listed in the guidelines as appropriate, but data supporting their respective efficacies are scarce. We summarize our institutional experience to try to fill the knowledge gap. Materials and Methods We retrospectively reviewed the medical records of differentiated thyroid cancer patients from 2006-2021 who underwent total thyroidectomy with or without radioactive iodine therapy with inoperable/unresectable recurrence in the thyroid bed and/or regional nodal regions and received intensity-modulated radiation therapy. The primary endpoint was progression free survival. Secondary endpoints include overall survival and radiation toxicities. Results Sixteen patients were identified (male 5, female 11), and the median age was 65 (42-90). All patients had papillary carcinoma and were regarded as iodine-refractory by the referring endocrinologist after having received salvage I-131 therapy with a median cumulative dose of 395 mCi (150-1050). Seven patients (43.7%) had stable lung metastasis before radiation treatment. The patients received intensity-modulated radiotherapy with a median dose of 6700 cGy (6000-7000) in conventional fractionation to the gross tumors with or without elective nodal regions. Ten patients (62.5%) had a more than 50% decrease in tumor markers (thyroglobulin or anti-thyroglobulin) after radiotherapy. Twelve patients (75%) had disease progression that required salvage therapy after radiotherapy (2 local progression, 9 distant progression, 1 both local and distant progression). Five patients received salvage tyrosine kinase inhibitor treatment. The median progression-free survival was 37.6 months (1-117.3), and the median overall survival was 51.8 months (4.2-143.6). The acute radiation toxicities were manageable and no patient had tube dependence or died of late radiation toxicities such as aspiration